Management of hypertension addressing hyperuricaemia: introduction of nano-based approaches

References

• Gonsalez SR, Cortês AL, Silva R, et al. Acute kidney injury overview: from basic findings to new prevention and therapy strategies. Pharmacol Ther. 2019;200:1–20. doi: 10.1016/j.pharmthera.2019.04.001.
   PubMed Web of Science ®Google Scholar
• Bagga HS, Chi T, Miller J, et al. New insights into the pathogenesis of renal calculi. Urol Clin North Am. 2013;40(1):1–12. doi: 10.1016/j.ucl.2012.09.006.
   PubMed Web of Science ®Google Scholar
• Devarajan A. Cross-talk between renal lithogenesis and atherosclerosis: an unveiled link between kidney stone formation and cardiovascular diseases. Clin Sci. 2018;132(6):615–626. doi: 10.1042/CS20171574.
   Web of Science ®Google Scholar
• Gambaro G, Croppi E, Coe F, et al. Metabolic diagnosis and medical prevention of calcium nephrolithiasis and its systemic manifestations: a consensus statement. J Nephrol. 2016;29(6):715–734. doi: 10.1007/s40620-016-0329-y.
   PubMed Web of Science ®Google Scholar
• Low RK, Stoller ML. Uric acid–related nephrolithiasis. Urol Clin North Am. 1997;24(1):135–148. doi: 10.1016/s0094-0143(05)70359-1.
   PubMed Web of Science ®Google Scholar
• Shekarriz B, Stoller ML. Uric acid nephrolithiasis: current concepts and controversies. J Urol. 2002;168(4 Pt 1):1307–1314. doi: 10.1016/S0022-5347(05)64439-4.
   PubMed Web of Science ®Google Scholar
• Abate N, Chandalia M, Cabo-Chan AV, et al. The metabolic syndrome and uric acid nephrolithiasis: novel features of renal manifestation of insulin resistance. Kidney Int. 2004;65(2):386–392. doi: 10.1111/j.1523-1755.2004.00386.x.
   PubMed Web of Science ®Google Scholar
• de Oliveira EP, Burini RC. High plasma uric acid concentration: causes and consequences. Diabetol Metab Syndr. 2012;4(1):12. doi: 10.1186/1758-5996-4-12.
   PubMed Web of Science ®Google Scholar
• Maiuolo J, Oppedisano F, Gratteri S, et al. Regulation of uric acid metabolism and excretion. Int J Cardiol. 2016;213:8–14. doi: 10.1016/j.ijcard.2015.08.109.
   PubMed Web of Science ®Google Scholar
• Borghi C, Agabiti-Rosei E, Johnson RJ, et al. Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease. Eur J Intern Med. 2020;80:1–11. doi: 10.1016/j.ejim.2020.07.006.
   PubMed Web of Science ®Google Scholar
• Johnson RJ, Bakris GL, Borghi C, et al. Hyperuricemia, acute and chronic kidney disease, hypertension, and cardiovascular disease: report of a scientific workshop organized by the national kidney foundation. Am J Kidney Dis. 2018;71(6):851–865. doi: 10.1053/j.ajkd.2017.12.009.
   PubMed Web of Science ®Google Scholar
• Bruce SP. Febuxostat: a selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout. Ann Pharmacother. 2006;40(12):2187–2194. doi: 10.1345/aph.1H121.
   PubMed Web of Science ®Google Scholar
• Suzuki S, Yoshihisa A, Yokokawa T, et al. Comparison between febuxostat and allopurinol uric acid-lowering therapy in patients with chronic heart failure and hyperuricemia: a multicenter randomized controlled trial. J Int Med Res. 2021;49(12):3000605211062770. 03000605211062770. doi: 10.1177/03000605211062770.
   Web of Science ®Google Scholar
• Hu M, Tomlinson B. Febuxostat in the management of hyperuricemia and chronic gout: a review. Ther Clin Risk Manag. 2008;4(6):1209–1220.
   PubMedGoogle Scholar
• Beara-Lasic L, Pillinger MH, Goldfarb DS. Advances in the management of gout: critical appraisal of febuxostat in the control of hyperuricemia. Int J Nephrol Renovasc Dis. 2010;3:1–10. doi: 10.2147/ijnrd.s5563.
   PubMedGoogle Scholar
• Borgi L, McMullan C, Wohlhueter A, et al. Effect of uric acid–lowering agents on endothelial function. Hypertension. 2017;69(2):243–248. doi: 10.1161/HYPERTENSIONAHA.116.08488.
   PubMed Web of Science ®Google Scholar
• Su H-y, Yang C, Liang D, et al. Research advances in the mechanisms of hyperuricemia-induced renal injury. Biomed Res Int. 2020;2020:5817348. doi: 10.1155/2020/5817348.
   PubMed Web of Science ®Google Scholar
• Cicero AFG, Fogacci F, Cincione RI, et al. Clinical effects of xanthine oxidase inhibitors in hyperuricemic patients. Med Princ Pract. 2021;30(2):122–130. doi: 10.1159/000512178.
   PubMed Web of Science ®Google Scholar
• Girigoswami K, Pallavi P, Girigoswami A. Intricate subcellular journey of nanoparticles to the enigmatic domains of endoplasmic reticulum. Drug Deliv. 2023;30(1):2284684. doi: 10.1080/10717544.2023.2284684.
   PubMed Web of Science ®Google Scholar
• Mary Lazer L, Sadhasivam B, Palaniyandi K, et al. Chitosan-based nano-formulation enhances the anticancer efficacy of hesperetin. Int J Biol Macromol. 2018;107(Pt B):1988–1998. doi: 10.1016/j.ijbiomac.2017.10.064.
   PubMed Web of Science ®Google Scholar
• Vedhanayagam M, Nidhin M, Duraipandy N, et al. Role of nanoparticle size in self-assemble processes of collagen for tissue engineering application. Int J Biol Macromol. 2017;99:655–664. doi: 10.1016/j.ijbiomac.2017.02.102.
   PubMed Web of Science ®Google Scholar
• Draviana HT, Fitriannisa I, Khafid M, et al. Size and charge effects of metal nanoclusters on antibacterial mechanisms. J Nanobiotechnol. 2023;21(1):428. doi: 10.1186/s12951-023-02208-3.
   PubMed Web of Science ®Google Scholar
• Pourmadadi M, Mahdi Eshaghi M, Ostovar S, et al. Innovative nanomaterials for cancer diagnosis, imaging, and therapy: drug delivery applications. J Drug Deliv Sci Technol. 2023;82:104357. doi: 10.1016/j.jddst.2023.104357.
   Web of Science ®Google Scholar
• Thirumalai A, Girigoswami K, Pallavi P, et al. Cancer therapy with iRGD as a tumor-penetrating peptide. Bull Cancer. 2023;110(12):1288–1300. doi: 10.1016/j.bulcan.2023.08.009.
   PubMed Web of Science ®Google Scholar
• Thirumalai A, Harini K, Pallavi P, et al. Bile salt-mediated surface-engineered bilosome-nanocarriers for delivering therapeutics. Nanomed J. 2024;11(1):1–12.
   Google Scholar
• Dragicevic N, Predic-Atkinson J, Nikolic B, et al. Nanocarriers in topical photodynamic therapy. Expert Opin Drug Deliv. 2024;21(2):279–307. doi: 10.1080/17425247.2024.2318460.
   PubMed Web of Science ®Google Scholar
• Pemula G, Anand AV, Karthick H, et al. Nanostructured proteins for delivering drugs to diseased tissues. Bioinspired Biomim Nanobiomaterials. 2023;12(3):115–129.
   Web of Science ®Google Scholar
• Shurfa MK, Girigoswami A, Sakthi Devi R, et al. Combinatorial effect of doxorubicin entrapped in alginate-chitosan hybrid polymer and cerium oxide nanocomposites on skin cancer management in mice. J Pharm Sci. 2023;112(11):2891–2900. doi: 10.1016/j.xphs.2023.08.014.
   PubMed Web of Science ®Google Scholar
• Naahidi S, Jafari M, Edalat F, et al. Biocompatibility of engineered nanoparticles for drug delivery. J Control Release. 2013;166(2):182–194. doi: 10.1016/j.jconrel.2012.12.013.
   PubMed Web of Science ®Google Scholar
• Otto DP, Otto A, de Villiers MM. Differences in physicochemical properties to consider in the design, evaluation and choice between microparticles and nanoparticles for drug delivery. Expert Opin Drug Deliv. 2015;12(5):763–777. doi: 10.1517/17425247.2015.988135.
   PubMed Web of Science ®Google Scholar
• Day Richard O, Kamel B, Kannangara Diluk RW, et al. Xanthine oxidoreductase and its inhibitors: relevance for gout. Clin Sci. 2016;130(23):2167–2180. doi: 10.1042/CS20160010.
   Web of Science ®Google Scholar
• Roman YM. The role of uric acid in human health: insights from the uricase gene. J Pers Med [Internet]. 2023;13(9):1409. doi: 10.3390/jpm13091409.
   PubMed Web of Science ®Google Scholar
• de Abreu MFS, Wegermann CA, Ceroullo MS, et al. Ten years milestones in xanthine oxidase inhibitors discovery: febuxostat-based inhibitors trends, bifunctional derivatives, and automatized screening assays. Organics [Internet]. 2022;3(4):380–414. doi: 10.3390/org3040026.
   Google Scholar
• Maia LB, Pereira V, Mira L, et al. Nitrite reductase activity of rat and human xanthine oxidase, xanthine dehydrogenase, and aldehyde oxidase: evaluation of their contribution to NO formation in vivo. Biochemistry. 2015;54(3):685–710. doi: 10.1021/bi500987w.
   PubMed Web of Science ®Google Scholar
• Agarwal A, Banerjee A, Banerjee UC. Xanthine oxidoreductase: a journey from purine metabolism to cardiovascular excitation-contraction coupling. Crit Rev Biotechnol. 2011;31(3):264–280. doi: 10.3109/07388551.2010.527823.
   PubMed Web of Science ®Google Scholar
• Nishino T, Okamoto K. The role of the [2Fe–2S] cluster centers in xanthine oxidoreductase. J Inorg Biochem. 2000;82(1–4):43–49. doi: 10.1016/s0162-0134(00)00165-3.
   PubMed Web of Science ®Google Scholar
• Harris CM, Sanders SA, Massey V. Role of the flavin midpoint potential and NAD binding in determining NAD versus oxygen reactivity of xanthine oxidoreductase. J Biol Chem. 1999;274(8):4561–4569. doi: 10.1074/jbc.274.8.4561.
   PubMed Web of Science ®Google Scholar
• Ribeiro PMG, Fernandes HS, Maia LB, et al. The complete catalytic mechanism of xanthine oxidase: a computational study. Inorg Chem Front. 2021;8(2):405–416. doi: 10.1039/D0QI01029D.
   Web of Science ®Google Scholar
• Ichida K, Amaya Y, Okamoto K, et al. Mutations associated with functional disorder of xanthine oxidoreductase and hereditary xanthinuria in humans. Int J Mol Sci [Internet]. 2012;13(11):15475–15495. doi: 10.3390/ijms131115475.
   PubMed Web of Science ®Google Scholar
• Cerqueira N, Pakhira B, Sarkar S. Theoretical studies on mechanisms of some Mo enzymes. J Biol Inorg Chem. 2015;20(2):323–335. doi: 10.1007/s00775-015-1237-7.
   PubMed Web of Science ®Google Scholar
• Unno T, Sugimoto A, Kakuda T. Scavenging effect of tea catechins and their epimers on superoxide anion radicals generated by a hypoxanthine and xanthine oxidase system. J Sci Food Agric. 2000;80(5):601–606. doi: 10.1002/(SICI)1097-0010(200004)80:5<601::AID-JSFA581>3.0.CO;2-O.
   Web of Science ®Google Scholar
• Hille R, Hall J, Basu P. The mononuclear molybdenum enzymes. Chem Rev. 2014;114(7):3963–4038. doi: 10.1021/cr400443z.
   PubMed Web of Science ®Google Scholar
• Berry CE, Hare JM. Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. J Physiol. 2004;555(Pt 3):589–606. doi: 10.1113/jphysiol.2003.055913.
   PubMed Web of Science ®Google Scholar
• Harrison R. Structure and function of xanthine oxidoreductase: where are we now? Free Radic Biol Med. 2002;33(6):774–797. doi: 10.1016/s0891-5849(02)00956-5.
   PubMed Web of Science ®Google Scholar
• Srinivasan S, Kalaiselvi P, Sakthivel R, et al. Uric acid: an abettor or protector in calcium oxalate urolithiasis? Biochemical study in stone formers. Clin Chim Acta. 2005;353(1–2):45–51. doi: 10.1016/j.cccn.2004.09.024.
   PubMed Web of Science ®Google Scholar
• Li L, Zhang Y, Zeng C. Update on the epidemiology, genetics, and therapeutic options of hyperuricemia. Am J Transl Res. 2020;12(7):3167–3181.
   PubMed Web of Science ®Google Scholar
• Vadakedath S, Kandi V. Probable potential role of urate transporter genes in the development of metabolic disorders. Cureus. 2018;10(3):e2382. doi: 10.7759/cureus.2382.
   PubMedGoogle Scholar
• Jin M, Yang F, Yang I, et al. Uric acid, hyperuricemia and vascular diseases. Front Biosci (Landmark Ed). 2012;17(2):656–669. doi: 10.2741/3950.
   PubMedGoogle Scholar
• Ridker PM, Wilson PWF, Grundy SM. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation. 2004;109(23):2818–2825. doi: 10.1161/01.CIR.0000132467.45278.59.
   PubMed Web of Science ®Google Scholar
• Ravindran S, Munusamy S. Renoprotective mechanisms of sodium-glucose co-transporter 2 (SGLT2) inhibitors against the progression of diabetic kidney disease. J Cell Physiol. 2022;237(2):1182–1205. doi: 10.1002/jcp.30621.
   PubMed Web of Science ®Google Scholar
• Sekine M, Okamoto K, Pai EF, et al. Allopurinol and oxypurinol differ in their strength and mechanisms of inhibition of xanthine oxidoreductase. J Biol Chem. 2023;299(9):105189. doi: 10.1016/j.jbc.2023.105189.
   PubMed Web of Science ®Google Scholar
• Torres RJ, Prior C, Puig JG. Efficacy and safety of allopurinol in patients with hypoxanthine-guanine phosphoribosyltransferase deficiency. Metabolism. 2007;56(9):1179–1186. doi: 10.1016/j.metabol.2007.04.013.
   PubMed Web of Science ®Google Scholar
• Maghsoud Y, Dong C, Cisneros GA. Investigation of the inhibition mechanism of xanthine oxidoreductase by oxipurinol: a computational study. J Chem Inf Model. 2023;63(13):4190–4206. doi: 10.1021/acs.jcim.3c00624.
   PubMed Web of Science ®Google Scholar
• Pál P, Nivorozhkin A, Csaba S. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev. 2006;58(1):87.
   PubMed Web of Science ®Google Scholar
• Stocker SL, Williams KM, McLachlan AJ, et al. Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in healthy subjects. Clin Pharmacokinet. 2008;47(2):111–118. doi: 10.2165/00003088-200847020-00004.
   PubMed Web of Science ®Google Scholar
• Day RO, Graham GG, Hicks M, et al. Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol. Clin Pharmacokinet. 2007;46(8):623–644. doi: 10.2165/00003088-200746080-00001.
   PubMed Web of Science ®Google Scholar
• Kumar R, Joshi G, Kler H, et al. Toward an understanding of structural insights of xanthine and aldehyde oxidases: an overview of their inhibitors and role in various diseases. Med Res Rev. 2018;38(4):1073–1125. doi: 10.1002/med.21457.
   PubMed Web of Science ®Google Scholar
• Cantor JR, Abu-Remaileh M, Kanarek N, et al. Physiologic medium rewires cellular metabolism and reveals uric acid as an endogenous inhibitor of UMP synthase. Cell. 2017;169(2):258–272. e17. doi: 10.1016/j.cell.2017.03.023.
   PubMed Web of Science ®Google Scholar
• Kamatani N, Jinnah HA, Hennekam RCM, et al. 6—Purine and pyrimidine metabolism. In: Pyeritz RE, Korf BR, Grody WW, editors. Emery and rimoin’s principles and practice of medical genetics and genomics. 7th ed. London, United Kingdom: Academic Press; 2021. p. 183–234.
   Google Scholar
• Sugamura K, Keaney JF. Reactive oxygen species in cardiovascular disease. Free Radic Biol Med. 2011;51(5):978–992. doi: 10.1016/j.freeradbiomed.2011.05.004.
   PubMed Web of Science ®Google Scholar
• van der Pol KH, Wever KE, Verbakel M, et al. Allopurinol to reduce cardiovascular morbidity and mortality: a systematic review and meta-analysis. PLoS One. 2021;16(12):e0260844. doi: 10.1371/journal.pone.0260844.
   PubMed Web of Science ®Google Scholar
• Gois PHF, Souza ERM. Pharmacotherapy for hyperuricaemia in hypertensive patients. Cochrane Database Syst Rev. 2020;9(9):Cd008652. doi: 10.1002/14651858.CD008652.pub4.
   PubMedGoogle Scholar
• Badve SV, Pascoe EM, Tiku A, et al. Effects of allopurinol on the progression of chronic kidney disease. N Engl J Med. 2020;382(26):2504–2513. doi: 10.1056/NEJMoa1915833.
   PubMed Web of Science ®Google Scholar
• Mackenzie IS, Hawkey CJ, Ford I, et al. Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial. Lancet. 2022;400(10359):1195–1205. doi: 10.1016/S0140-6736(22)01657-9.
   PubMed Web of Science ®Google Scholar
• ElShagea HN, ElKasabgy NA, Fahmy RH, et al. Freeze-Dried Self-Nanoemulsifying Self-Nanosuspension (SNESNS): a new approach for the preparation of a highly drug-loaded dosage form. AAPS PharmSciTech. 2019;20(7):258. doi: 10.1208/s12249-019-1472-2.
   PubMed Web of Science ®Google Scholar
• Mukoyoshi M, Nishimura S, Hoshide S, et al. In vitro drug–drug interaction studies with febuxostat, a novel non-purine selective inhibitor of xanthine oxidase: plasma protein binding, identification of metabolic enzymes and cytochrome P450 inhibition. Xenobiotica. 2008;38(5):496–510. doi: 10.1080/00498250801956350.
   PubMed Web of Science ®Google Scholar
• Love BL, Barrons R, Veverka A, et al. Urate-Lowering therapy for gout: focus on febuxostat. Pharmacotherapy: J Hum Pharmacol Drug Ther. 2010;30(6):594–608. doi: 10.1592/phco.30.6.594.
   Google Scholar
• Kamel B, Graham GG, Stocker SL, et al. A pharmacokinetic-pharmacodynamic study of a single dose of febuxostat in healthy subjects. Br J Clin Pharmacol. 2020;86(12):2486–2496. doi: 10.1111/bcp.14357.
   PubMed Web of Science ®Google Scholar
• Ernst ME, Fravel MA. Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout. Clin Ther. 2009;31(11):2503–2518. doi: 10.1016/j.clinthera.2009.11.033.
   PubMed Web of Science ®Google Scholar
• Strilchuk L, Fogacci F, Cicero AF. Safety and tolerability of available urate-lowering drugs: a critical review. Expert Opin Drug Saf. 2019;18(4):261–271. doi: 10.1080/14740338.2019.1594771.
   PubMed Web of Science ®Google Scholar
• O’Dell JR, Brophy MT, Pillinger MH, et al. Comparative effectiveness of allopurinol and febuxostat in gout management. NEJM Evid. 2022;1(3):EVIDoa2100028. doi: 10.1056/evidoa2100028.
   Google Scholar
• Zhang F, Liu Z, Jiang L, et al. A randomized, double-Blind, non-Inferiority study of febuxostat versus allopurinol in hyperuricemic Chinese subjects with or without gout. Rheumatol Ther. 2019;6(4):543–557. doi: 10.1007/s40744-019-00173-8.
   PubMed Web of Science ®Google Scholar
• Peng Y-L, Tain Y-L, Lee C-T, et al. Comparison of uric acid reduction and renal outcomes of febuxostat vs allopurinol in patients with chronic kidney disease. Sci Rep. 2020;10(1):10734. doi: 10.1038/s41598-020-67026-1.
   PubMed Web of Science ®Google Scholar
• Pawar A, Desai RJ, Liu J, et al. Updated assessment of cardiovascular risk in older patients with gout initiating febuxostat versus allopurinol. J Am Heart Assoc. 2021;10(7):e020045. doi: 10.1161/JAHA.120.020045.
   PubMed Web of Science ®Google Scholar
• Kim H, Baek CH, Chang JW, et al. Febuxostat, a novel inhibitor of xanthine oxidase, reduces ER stress through upregulation of SIRT1-AMPK-HO-1/thioredoxin expression. Clin Exp Nephrol. 2020;24(3):205–215. doi: 10.1007/s10157-019-01804-8.
   PubMed Web of Science ®Google Scholar
• Nomura J, Kobayashi T, So A, et al. Febuxostat, a xanthine oxidoreductase inhibitor, decreases NLRP3-dependent inflammation in macrophages by activating the purine salvage pathway and restoring cellular bioenergetics. Sci Rep. 2019;9(1):17314. doi: 10.1038/s41598-019-53965-x.
   PubMedGoogle Scholar
• Amirshahrokhi K. Febuxostat attenuates ulcerative colitis by the inhibition of NF-κB, proinflammatory cytokines, and oxidative stress in mice. Int Immunopharmacol. 2019;76:105884. doi: 10.1016/j.intimp.2019.105884.
   PubMed Web of Science ®Google Scholar
• Odake K, Tsujii M, Iino T, et al. Febuxostat treatment attenuates oxidative stress and inflammation due to ischemia-reperfusion injury through the necrotic pathway in skin flap of animal model. Free Radic Biol Med. 2021;177:238–246. doi: 10.1016/j.freeradbiomed.2021.10.033.
   PubMed Web of Science ®Google Scholar
• Ashtar M, Tenshin H, Teramachi J, et al. The roles of ROS generation in RANKL-Induced osteoclastogenesis: suppressive effects of febuxostat. Cancers [Internet]. 2020;12(4):929. doi: 10.3390/cancers12040929.
   PubMed Web of Science ®Google Scholar
• Higa Y, Hiasa M, Tenshin H, et al. The xanthine oxidase inhibitor febuxostat suppresses adipogenesis and activates Nrf2. Antioxidants [Internet]. 2023;12(1):133. doi: 10.3390/antiox12010133.
   Web of Science ®Google Scholar
• Abdel-Wahab BA, El-Shoura EAM, Shafiuddin Habeeb M, et al. Febuxostat alleviates arsenic Trioxide-Induced renal injury in rats: insights on the crosstalk between NLRP3/TLR4, sirt-1/NF-κB/TGF-β signaling pathways, and miR-23b-3p, miR-181a-5b expression. Biochem Pharmacol. 2023;216:115794. doi: 10.1016/j.bcp.2023.115794.
   PubMed Web of Science ®Google Scholar
• Zhang C, Tang L, Zhang Y, et al. Febuxostat, a xanthine oxidase inhibitor, regulated long noncoding RNAs and protected the brain after intracerebral hemorrhage. NeuroReport. 2023;34(14):703–712. doi: 10.1097/WNR.0000000000001945.
   PubMed Web of Science ®Google Scholar
• Yan W, Zhang Y, Hu L, et al. Febuxostat inhibits MPP+-induced inflammatory response through inhibiting the JNK/NF-κB pathway in astrocytes. Neurotox Res. 2021;39(3):566–574. doi: 10.1007/s12640-020-00316-8.
   PubMed Web of Science ®Google Scholar
• Lanaspa MA, Andres-Hernando A, Kuwabara M. Uric acid and hypertension. Hypertens Res. 2020;43(8):832–834. doi: 10.1038/s41440-020-0481-6.
   PubMed Web of Science ®Google Scholar
• Kuwabara M, Niwa K, Nishi Y, et al. Relationship between serum uric acid levels and hypertension among Japanese individuals not treated for hyperuricemia and hypertension. Hypertens Res. 2014;37(8):785–789. doi: 10.1038/hr.2014.75.
   PubMed Web of Science ®Google Scholar
• Kuwabara M, Hisatome I, Niwa K, et al. Uric acid is a strong risk marker for developing hypertension from prehypertension. Hypertension. 2018;71(1):78–86. doi: 10.1161/HYPERTENSIONAHA.117.10370.
   PubMed Web of Science ®Google Scholar
• Bove M, Cicero AFG, Borghi C. The effect of xanthine oxidase inhibitors on blood pressure and renal function. Curr Hypertens Rep. 2017;19(12):95. doi: 10.1007/s11906-017-0793-3.
   PubMed Web of Science ®Google Scholar
• Kuwabara M, Kanbay M, Hisatome I. Uric acid and hypertension because of arterial stiffness. Hypertension. 2018;72(3):582–584. doi: 10.1161/HYPERTENSIONAHA.118.11496.
   PubMed Web of Science ®Google Scholar
• Dikalov SI, Ungvari Z. Role of mitochondrial oxidative stress in hypertension. Am J Physiol Heart Circ Physiol. 2013;305(10):H1417–H1427. doi: 10.1152/ajpheart.00089.2013.
   PubMed Web of Science ®Google Scholar
• Zhang B, Duan M, Long B, et al. Urate transport capacity of glucose transporter 9 and urate transporter 1 in cartilage chondrocytes. Mol Med Rep. 2019;20(2):1645–1654.
   PubMed Web of Science ®Google Scholar
• Bhatnagar A. Environmental determinants of cardiovascular disease. Circ Res. 2017;121(2):162–180. doi: 10.1161/CIRCRESAHA.117.306458.
   PubMed Web of Science ®Google Scholar
• Lee T-S, Lu T-M, Chen C-H, et al. Hyperuricemia induces endothelial dysfunction and accelerates atherosclerosis by disturbing the asymmetric dimethylarginine/dimethylarginine dimethylaminotransferase 2 pathway. Redox Biol. 2021;46:102108. doi: 10.1016/j.redox.2021.102108.
   PubMed Web of Science ®Google Scholar
• Wang A, Tian X, Wu S, et al. Metabolic factors mediate the association between serum uric acid to serum creatinine ratio and cardiovascular disease. J Am Heart Assoc. 2021;10(23):e023054. doi: 10.1161/JAHA.121.023054.
   PubMed Web of Science ®Google Scholar
• Tian X, Zuo Y, Chen S, et al. Associations between changes in serum uric acid and the risk of myocardial infarction. Int J Cardiol. 2020;314:25–31. doi: 10.1016/j.ijcard.2020.03.083.
   PubMed Web of Science ®Google Scholar
• Maloberti A, Mengozzi A, Russo E, et al. The results of the URRAH (Uric Acid Right for Heart Health) project: a focus on hyperuricemia in relation to cardiovascular and kidney disease and its role in metabolic dysregulation. High Blood Press Cardiovasc Prev. 2023;30(5):411–425. doi: 10.1007/s40292-023-00602-4.
   PubMed Web of Science ®Google Scholar
• Maloberti A, Giannattasio C, Bombelli M, et al. Hyperuricemia and risk of cardiovascular outcomes: the experience of the URRAH (Uric Acid Right for Heart Health) project. High Blood Press Cardiovasc Prev. 2020;27(2):121–128. doi: 10.1007/s40292-020-00368-z.
   PubMed Web of Science ®Google Scholar
• Russo E, Viazzi F, Pontremoli R, et al. Association of uric acid with kidney function and albuminuria: the Uric Acid Right for heArt Hhealth (URRAH) project. J Nephrol. 2022;35(1):211–221. doi: 10.1007/s40620-021-00985-4.
   PubMed Web of Science ®Google Scholar
• Casiglia E, Tikhonoff V, Virdis A, et al. Serum uric acid/serum creatinine ratio as a predictor of cardiovascular events. Detection of prognostic cardiovascular cut-off values. J Hypertens. 2023;41(1):180–186. doi: 10.1097/HJH.0000000000003319.
   PubMed Web of Science ®Google Scholar
• Scheepers LEJM, Wei F-F, Stolarz-Skrzypek K, et al. Xanthine oxidase gene variants and their association with blood pressure and incident hypertension: a population study. J Hypertens. 2016;34(11):2147–2154. doi: 10.1097/HJH.0000000000001077.
   PubMed Web of Science ®Google Scholar
• Miah R, Fariha KA, Sony SA, et al. Association of serum xanthine oxidase levels with hypertension: a study on Bangladeshi adults. Sci Rep. 2022;12(1):21727. doi: 10.1038/s41598-022-26341-5.
   PubMed Web of Science ®Google Scholar
• Viel EC, Benkirane K, Javeshghani D, et al. Xanthine oxidase and mitochondria contribute to vascular superoxide anion generation in DOCA-salt hypertensive rats. Am J Physiol Heart Circ Physiol. 2008;295(1):H281–H288. doi: 10.1152/ajpheart.00304.2008.
   PubMed Web of Science ®Google Scholar
• Boban M, Kocic G, Radenkovic S, et al. Circulating purine compounds, uric acid, and xanthine oxidase/dehydrogenase relationship in essential hypertension and end stage renal disease. Ren Fail. 2014;36(4):613–618. doi: 10.3109/0886022X.2014.882240.
   PubMed Web of Science ®Google Scholar
• Jankov RP, Kantores C, Pan J, et al. Contribution of xanthine oxidase-derived superoxide to chronic hypoxic pulmonary hypertension in neonatal rats. Am J Physiol Lung Cell Mol Physiol. 2008;294(2):L233–L245. doi: 10.1152/ajplung.00166.2007.
   PubMed Web of Science ®Google Scholar
• Furuhashi M, Higashiura Y, Koyama M, et al. Independent association of plasma xanthine oxidoreductase activity with hypertension in nondiabetic subjects not using medication. Hypertens Res. 2021;44(9):1213–1220. doi: 10.1038/s41440-021-00679-1.
   PubMed Web of Science ®Google Scholar
• Kurajoh M, Fukumoto S, Yoshida S, et al. Uric acid shown to contribute to increased oxidative stress level independent of xanthine oxidoreductase activity in MedCity21 health examination registry. Sci Rep. 2021;11(1):7378. doi: 10.1038/s41598-021-86962-0.
   PubMed Web of Science ®Google Scholar
• Muraya N, Kadowaki D, Miyamura S, et al. Benzbromarone attenuates oxidative stress in angiotensin II- and Salt-Induced hypertensive model rats. Oxid Med Cell Longev. 2018;2018:7635274–7635278. doi: 10.1155/2018/7635274.
   PubMed Web of Science ®Google Scholar
• Yun L, Yu X, Xu R. Uric acid/superoxide dismutase can predict progression of gestational hypertension to preeclampsia. Front Cardiovasc Med. 2023;10:1148376. doi: 10.3389/fcvm.2023.1148376.
   PubMed Web of Science ®Google Scholar
• Trapé AA, Jacomini AM, Muniz JJ, et al. The relationship between training status, blood pressure and uric acid in adults and elderly. BMC Cardiovasc Disord. 2013;13(1):44. doi: 10.1186/1471-2261-13-44.
   PubMedGoogle Scholar
• Tsukimori K, Yoshitomi T, Morokuma S, et al. Serum uric acid levels correlate with plasma hydrogen peroxide and protein carbonyl levels in preeclampsia. Am J Hypertens. 2008;21(12):1343–1346. doi: 10.1038/ajh.2008.289.
   PubMed Web of Science ®Google Scholar
• Zhang J, Zheng R, Li H, et al. Serum uric acid and incident atrial fibrillation: a systematic review and dose–response meta-analysis. Clin Exp Pharmacol Physiol. 2020;47(11):1774–1782. doi: 10.1111/1440-1681.13374.
   PubMed Web of Science ®Google Scholar
• Kawasoe S, Kubozono T, Yoshifuku S, et al. Uric acid level and prevalence of atrial fibrillation in a Japanese general population of 285,882. Circ J. 2016;80(12):2453–2459. doi: 10.1253/circj.CJ-16-0766.
   PubMed Web of Science ®Google Scholar
• Ding M, Viet NN, Gigante B, et al. Elevated uric acid is associated with new‐onset atrial fibrillation: results from the Swedish AMORIS cohort. J Am Heart Assoc. 2023;12(3):e027089. doi: 10.1161/JAHA.122.027089.
   PubMed Web of Science ®Google Scholar
• Deng Y, Liu F, Yang X, et al. The key role of uric acid in oxidative stress, inflammation, fibrosis, apoptosis, and immunity in the pathogenesis of atrial fibrillation. Front Cardiovasc Med. 2021;8:641136. doi: 10.3389/fcvm.2021.641136.
   PubMed Web of Science ®Google Scholar
• Perez-Ruiz F, Dalbeth N, Bardin T. A review of uric acid, crystal deposition disease, and gout. Adv Ther. 2015;32(1):31–41. doi: 10.1007/s12325-014-0175-z.
   PubMed Web of Science ®Google Scholar
• Johnson RJ, Sanchez Lozada LG, Lanaspa MA, et al. Uric acid and chronic kidney disease: still more to do. Kidney Int Rep. 2023;8(2):229–239. doi: 10.1016/j.ekir.2022.11.016.
   PubMed Web of Science ®Google Scholar
• Singh JA, Cleveland JD. Comparative effectiveness of allopurinol versus febuxostat for preventing incident dementia in older adults: a propensity-matched analysis. Arthritis Res Ther. 2018;20(1):167. doi: 10.1186/s13075-018-1663-3.
   PubMedGoogle Scholar
• Kushiyama A, Nakatsu Y, Matsunaga Y, et al. Role of uric acid metabolism-related inflammation in the pathogenesis of metabolic syndrome components such as atherosclerosis and nonalcoholic steatohepatitis. Mediators Inflamm. 2016;2016:8603115–8603164. doi: 10.1155/2016/8603164.
   Web of Science ®Google Scholar
• Sandoo A, van Zanten JJ, Metsios GS, et al. The endothelium and its role in regulating vascular tone. Open Cardiovasc Med J. 2010;4(1):302–312. doi: 10.2174/1874192401004010302.
   PubMedGoogle Scholar
• Grover-Páez F, Zavalza-Gómez AB. Endothelial dysfunction and cardiovascular risk factors. Diabetes Res Clin Pract. 2009;84(1):1–10. doi: 10.1016/j.diabres.2008.12.013.
   PubMed Web of Science ®Google Scholar
• Chen C, Lü JM, Yao Q. Hyperuricemia-Related diseases and xanthine oxidoreductase (XOR) inhibitors: an overview. Med Sci Monit. 2016;22:2501–2512. doi: 10.12659/msm.899852.
   PubMed Web of Science ®Google Scholar
• Pallavi P, Harini K, Alshehri S, et al. From synthetic route of silica nanoparticles to theranostic applications. Processes. 2022;10(12):2595. doi: 10.3390/pr10122595.
   Web of Science ®Google Scholar
• Bhoopathy J, Vedakumari Sathyaraj W, Yesudhason BV, et al. Haemostatic potency of sodium alginate/aloe vera/sericin composite scaffolds—preparation, characterisation, and evaluation. Artif Cells Nanomed Biotechnol. 2024;52(1):35–45. doi: 10.1080/21691401.2023.2293784.
   PubMed Web of Science ®Google Scholar
• Girigoswami K, Pallavi P, Girigoswami A. Targeting cancer stem cells by nanoenabled drug delivery. In: Pathak S, Banerjee A, editors. Cancer stem cells: new horizons in cancer therapies. Singapore: Springer Singapore; 2020. p. 313–337.
   Google Scholar
• Vedakumari SW, Prabu P, Jancy SJV, et al. Radiopaque fibrin nanocomplex as a promising tool for X-ray ­imaging applications. Int J Biol Macromol. 2022;200:285–292. doi: 10.1016/j.ijbiomac.2021.12.164.
   PubMed Web of Science ®Google Scholar
• Gowtham P, Girigoswami K, Pallavi P, et al. Alginate-Derivative encapsulated carbon coated Manganese-Ferrite nanodots for multimodal medical imaging. Pharmaceutics. 2022;14(12):2550. doi: 10.3390/pharmaceutics14122550.
   PubMed Web of Science ®Google Scholar
• Paramita P, Subramaniam VD, Murugesan R, et al. Evaluation of potential anti‐cancer activity of cationic liposomal nanoformulated lycopodium clavatum in colon cancer cells. IET Nanobiotechnol. 2018;12(6):727–732. doi: 10.1049/iet-nbt.2017.0106.
   PubMed Web of Science ®Google Scholar
• Jessy Mercy D, Girigoswami K, Girigoswami A. A mini review on biosensor advancements-emphasis on quantum dots. Results Chem. 2024;7:101271. doi: 10.1016/j.rechem.2023.101271.
   Google Scholar
• Bhatt S, Sharma JB, Kamboj R, et al. Design and optimization of febuxostat-loaded nano lipid carriers using full factorial design. Turk J Pharm Sci. 2021;18(1):61–67. doi: 10.4274/tjps.galenos.2019.32656.
   PubMed Web of Science ®Google Scholar
• Gurumukhi VC, Sonawane VP, Tapadiya GG, et al. Quality-by-design based fabrication of febuxostat-loaded nanoemulsion: statistical optimization, characterizations, permeability, and bioavailability studies. Heliyon. 2023;9(4):e15404. doi: 10.1016/j.heliyon.2023.e15404.
   PubMed Web of Science ®Google Scholar
• Al-Amodi YA, Hosny KM, Alharbi WS, et al. Investigating the potential of transmucosal delivery of febuxostat from oral lyophilized tablets loaded with a self-nanoemulsifying delivery system. Pharmaceutics [Internet]. 2020;12(6):534. doi: 10.3390/pharmaceutics12060534.
   PubMed Web of Science ®Google Scholar
• Singh S, Parashar P, Kanoujia J, et al. Transdermal potential and anti-gout efficacy of febuxostat from niosomal gel. J Drug Deliv Sci Technol. 2017;39:348–361. doi: 10.1016/j.jddst.2017.04.020.
   Web of Science ®Google Scholar
• Patel B, Thakkar H. Formulation development of fast dissolving microneedles loaded with cubosomes of febuxostat: in vitro and in vivo evaluation. Pharmaceutics [Internet]. 2023;15(1):224. doi: 10.3390/pharmaceutics15010224.
   PubMed Web of Science ®Google Scholar
• Ali Z, Din FU, Zahid F, et al. Transdermal delivery of allopurinol-loaded nanostructured lipid carrier in the treatment of gout. BMC Pharmacol Toxicol. 2022;23(1):86. doi: 10.1186/s40360-022-00625-y.
   PubMed Web of Science ®Google Scholar
• Kandav G, Bhatt DC, Singh SK. Effect of different molecular weights of chitosan on formulation and evaluation of allopurinol-loaded nanoparticles for kidney targeting and in management of hyperuricemic nephrolithiasis. AAPS PharmSciTech. 2022;23(5):144. doi: 10.1208/s12249-022-02297-7.
   PubMed Web of Science ®Google Scholar
• Kandav G, Bhatt DC, Jindal DK, et al. Formulation, optimization, and evaluation of allopurinol-loaded bovine serum albumin nanoparticles for targeting kidney in management of hyperuricemic nephrolithiasis. AAPS PharmSciTech. 2020;21(5):164. doi: 10.1208/s12249-020-01695-z.
   PubMed Web of Science ®Google Scholar
• Abdulaal WH, Alhakamy NA, Hosny KM. Preparation and characterization of a thioctic acid nanostructured lipid carrier to enhance the absorption profile and limit the nephrotoxicity associated with allopurinol in the treatment of gout. J Drug Deliv Sci Technol. 2021;66:102859. doi: 10.1016/j.jddst.2021.102859.
   Web of Science ®Google Scholar
• Ahuja BK, Jena SK, Paidi SK, et al. Formulation, optimization and in vitro–in vivo evaluation of febuxostat nanosuspension. Int J Pharm. 2015;478(2):540–552. doi: 10.1016/j.ijpharm.2014.12.003.
   PubMed Web of Science ®Google Scholar
• Amin OM, Ammar A, Eladawy SA. Febuxostat loaded β-cyclodextrin based nanosponge tablet: an in vitro and in vivo evaluation. J Pharm Investig. 2020;50(4):399–411. doi: 10.1007/s40005-019-00464-w.
   Web of Science ®Google Scholar
• Tayyab M, Haseeb MT, Alsahli TG, et al. Fabrication and optimization of febuxostat-loaded chitosan nanocarriers for better pharmacokinetics profile. Int J Biol Macromol. 2024;257(Pt 1):128448. doi: 10.1016/j.ijbiomac.2023.128448.
   PubMedGoogle Scholar
• Sun J, Du J, Liu X, et al. Preparation of chitosan-coated hollow tin dioxide nanoparticles and their application in improving the oral bioavailability of febuxostat. Int J Pharm: X. 2023;6:100199.
   PubMedGoogle Scholar
• Aganyants HA, Nikohosyan G, Danielyan KE. Albumin microparticles as the carriers for allopurinol and applicable for the treatment of ischemic stroke. Int Nano Lett. 2016;6(1):35–40. doi: 10.1007/s40089-015-0169-0.
   Google Scholar
• Ye L, Gao Z, Rohani S. Intervertebral disk regeneration in a rat model by allopurinol–loaded chitosan/alginate hydrogel. Biomol Biomed. 2023;23(4):661–670. doi: 10.17305/bb.2022.8550.
   PubMedGoogle Scholar
• Sharma N, Kumar S, Joshi G, et al. Formulation and characterization of febuxostat loaded nanostructured lipid carriers (NLCs)-gel for topical treatment of gout. Recent Pat Nanotechnol. 2022;16(3):250–258. doi: 10.2174/1872210515666210415114118.
   PubMed Web of Science ®Google Scholar
• El-Shenawy AA, Abdelhafez WA, Ismail A, et al. Formulation and characterization of nanosized ethosomal formulations of antigout model drug (febuxostat) prepared by cold method: in vitro/ex vivo and in vivo assessment. AAPS PharmSciTech. 2019;21(1):31. doi: 10.1208/s12249-019-1556-z.
   PubMed Web of Science ®Google Scholar
• Battelli MG, Bortolotti M, Polito L, et al. The role of xanthine oxidoreductase and uric acid in metabolic syndrome. Biochim Biophys Acta Mol Basis Dis. 2018;1864(8):2557–2565. doi: 10.1016/j.bbadis.2018.05.003.
   PubMed Web of Science ®Google Scholar
• Benn CL, Dua P, Gurrell R, et al. Physiology of hyperuricemia and urate-lowering treatments. Front Med. 2018;5:160. doi: 10.3389/fmed.2018.00160.
   PubMed Web of Science ®Google Scholar
• Hyon KC, Lucia Cea S, Yuqing Z, et al. Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study. BMJ. 2012;344:d8190.
   PubMedGoogle Scholar
• Ganesan T, Muthudoss P, Voguri RS, et al. A new febuxostat-telmisartan drug-drug cocrystal for gout-hypertension combination therapy. J Pharm Sci. 2022;111(12):3318–3326. doi: 10.1016/j.xphs.2022.08.022.
   PubMed Web of Science ®Google Scholar